DeepCDR's algorithms can generate large panels of fully human antibody sequences. Using these sequences, Twist has built multiple fully human synthetic antibody libraries, specifically a hypermutated single-chain, fragment-variable library and a new coronavirus-specific single-chain, fragment-variable library, company officials said.

Twist's platform uses a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip, the company said.

Twist inks collaboration deal with Adicet Bio
Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies.

Boehringer, Twist to collaborate on antibody discovery
Boehringer Ingelheim and Twist Bioscience have entered a research collaboration to discover therapeutic antibodies against multiple targets.

How challenging risky ideas fuels the research ecosystem
If you knew that an experiment would fail, would it be worthwhile to conduct if it had the potential to challenge fundamental hypotheses about science?...

Twist reports revenue increases for Q3
Twist Bioscience reported revenue increases for the third quarter of fiscal 2021, which ended June 30.

Twist incorporates Molcure AI into antibody discovery efforts
Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.